|
Clinical and Laboratory Study of Methylmalonic Acidemia Clinical Trials References presented on Clinical Trials Search isn't meant to be a substitute for proven healthcare advice, trips or professional assistance using a genuine physician. We are not docs. Always confer with your physician about Clinical and Laboratory Study of Methylmalonic Acidemia conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Clinical and Laboratory Study of Methylmalonic Acidemia Clinical research trials and Clinical and Laboratory Study of Methylmalonic Acidemia healthcare trials happen in hundreds of localities throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the potency of new drugs. The propose of the studies / projects is to answer particular human health questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to detect cures for all sorts of conditions, such as Clinical and Laboratory Study of Methylmalonic Acidemia. Clinical and Laboratory Study of Methylmalonic Acidemia Clinical Trials and other clinical trials allow volunteers to acquire healthcare treatment choices before they are available to the general public. Some times the subjects recieve professional assistance for free, and every now and again they are compensated for their time. Sometimes there is a cost for a Clinical and Laboratory Study of Methylmalonic Acidemia clinical trial. Subjects frequently obtain the most expert healthcare possible for their Clinical and Laboratory Study of Methylmalonic Acidemia condition. Risks are a reality, nevertheless, and can include more or frequent doctor trips, medical risks (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with stern guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Clinical and Laboratory Study of Methylmalonic Acidemia  Clinical and Laboratory Study of Methylmalonic Acidemia
Clinical and Laboratory Study of Methylmalonic Acidemia
For Condition:
Status: Recruiting
Sponsor(s): National Human Genome Research Institute (NHGRI) ,
Synopsis: This study will evaluate patients with methylmalonic acidemia (MMA) to learn more about the genetic causes of the various types of this inherited metabolic disorder and the medical complications associated with it. People with MMA may have problems with learning and development and kidney malfunctioning. They can become seriously ill, sometimes with little warning. There is no cure for any MMA, but special diets and vitamin therapies are used for treatment. Patients between 2 and 70 years of age with MMA may be eligible for this study. Participants are admitted to the NIH Clinical Center for 4-5 days each year for 5-10 years for the following tests and procedures: -Medical history, physical examination, eye examination -Consultations from dentists and specialists in the nervous system, digestive tract, endocrine, and kidney, as needed. -24-hour urine collection to examine for methylmalonic acid, other acids, sugar, and proteins for measuring kidney function. -Blood test to assess liver and thyroid function, blood counts and blood chemistries, methylmalonic acid levels, and for genetic tests and basic research studies. -Blood test to measure growth hormone production. For this test, a very small amount of blood is collected overnight (every 20-30 minutes from 8:00 PM to 8:00 AM) through an intravenous catheter (plastic tube placed in a vein). The total amount of blood drawn is approximately 1 tablespoon. Patients who have stopped growing or whose weight does not permit collection of 1 tablespoon of blood do not undergo this procedure. -Frequent blood pressure measurements, including overnight monitoring -Skin biopsy for cell culture (cells to grow in the laboratory for future testing). For this procedure, an area of skin is numbed with an anesthetic such as lidocaine. A 4-mm diameter circular area is then removed using a sharp punch and scissors. The wound is dressed and usually heals within a week. -Photographs of the face and body (wearing underwear) to help track growth and appearance. -Ultrasound of the kidneys -Hand x-ray to determine bone age -Dual energy x-ray absorptionometry (DEXA) scan to assess bone density. For the DEXA scan, the patient lies still on a table while the spine and hip are scanned using a small amount of radiation. Any patient who becomes seriously ill during the evaluation may be cared for at the NIH or transferred to another hospital if it is deemed advisable.
Details: Inborn errors of metabolism comprise a heterogeneous group of genetic disorders that collectively are relatively common in the population. Many are associated with significant childhood morbidity and mortality as well as substantial health care utilization. Modern newborn screening methodologies that utilize tandem mass spectrometry (MS/MS) have allowed the diagnosis of presymptomatic, affected patients with various metabolic disorders. However, limited progress has been made to develop new treatments, in part because the natural histories of the disease states are not fully understood. One group of inborn errors, the hereditary methylmalonic acidemias (MMA), appears prototypical in this regard as patients can now be diagnosed via increased propionylcarnitine on newborn screening. Methylmalonic acidemia is heterogeneous, clinically and biochemically. Several different complementation groups exist. The isolated methylmalonyl-CoA mutase deficiency disorders, defined by the cblA, cblB, cblH, and mut complementation classes, share a common defect in the activity of the adenosylcobalamin-dependent enzyme, methylmalonyl-CoA mutase. Affected patients exhibit extreme elevations of methylmalonic acid in all tissues and body fluids and are metabolically fragile. No definitive treatment exists, although some patients have benefited from liver, kidney, and combined hepato-renal transplantation. Among the complications of isolated MMA, the high incidence of mental retardation and propensity toward basal ganglia infarctions of the brain, growth problems, and renal disease stand out as areas that require epidemiological definition, clinical characterization and scientific analysis. The cobalamin deficiency disorders, cobalamin C (cblC), cobalamin D (cblD), and cobalamin F (cblF) all exhibit a combined deficiency of the two vitamin B12-dependent enzymes, methylmalonyl-CoA mutase and methionine synthase. The pathophysiological features of these disorders are likely related to an impaired transsulfuration cycle, since the patients have hyperhomocyst(e)inemia in body fluids and tissues with concomitant hypomethioninemia. There is great clinical heterogeneity in these disorders, with presentations ranging from crisis in the neonatal period, to reversible dementia in adolescence. Patients suffer from multi-organ system involvement and would greatly benefit from prospective clinical characterization and scientific investigation, especially since the underlying genetic defects remain unknown. In this protocol, we will clinically evaluate patients with methymalonic acidemia and cobalamin metabolic defects. We will define and characterize a patient population, obtain cells and urine, perform mutation analysis in known genes, and search for the causative genes when the molecular basis of the complementation class is uncertain. Routine inpatient admissions will last 4-5 days and occur every year. They will involve urine collection, blood drawing, ophthalmologic examination, radiological procedures, skin biopsies, and developmental testing.
Eligibility:
Study Type: Observational, Natural History
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: MMA patients of any gender and ethnicity age 2-70 years are eligible to enroll in this protocol. Patients will be diagnosed based on a determination of MMA and homocysteine levels in plasma and urine. Most will have their complementation class known or pending. Some patients who have not yet had this laboratory test will be admitted tothe protocol based upon metabolic parameters and clinical history. EXCLUSION CRITERIA: Patients will be excluded if they cannot travel to the NIH because of their medical condition or are less than 2 years of age. Other criteria include residing in a hospital, sub-optimal metabolic control as determined by Dr. Venditti's review of the laboratory data, any patient who requires dialysis once or more/weekand weighs less than 40 kg, any patient who is being treated for an intercurrent infection with antibiotics or has evidence of an acute infection, and any patient who does not have a regular/local metabolic, genetic or endocrine physician and/or a family physician, pediatrician, or internist.
Total Enrollment: 600
Location and Contact Information:
National Human Genome Research Institute (NHGRI) *Recruiting*
Bethesda, Maryland, 20892
United States
Recruiting Patient and Public Liaison Office 1-800-411-1222
Additional Information:
Study ID Numbers: 040127; 04-HG-0127
Study Start Date: February 17, 2004
Record last reviewed: December 10, 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00078078
Related Studies:
Other Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Clinical and Laboratory Study of Methylmalonic Acidemia
|
|
|
|
|
|
|
|
